Capital/Financing Update • Jan 8, 2016
Capital/Financing Update
Open in ViewerOpens in native device viewer
REGULATED INFORMATION REGULATED INFORMATION REGULATED INFORMATION
Paris and Boston, January 8, 2016 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.
The liquidity account had the following holdings as of December 31, 2015:
For the prior (June 30, 2015), the corresponding figures were:
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 [email protected]
Investor Relations / Financial Communications – NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.